Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.41 |
| ▸ | STS | P08842 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845237 | 1.00 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL2215975 | 0.92 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3847372 | 0.91 | SMN1; SMN2 (0.37) | CA2STSESR1RORC | |
| SCHEMBL3847345 | 0.88 | RORC (0.33) | CA2ESR1RORC | |
| SCHEMBL2213456 | 0.88 | CA2 (0.35) | CA2STSESR1SOD1CA1 | |
| SCHEMBL5172821 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL2214509 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL5149829 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3845724 | 0.84 | CA2 (0.41) | CA2STSESR1SOD1CA1 | |
| SCHEMBL3847363 | 0.83 | SMN1; SMN2 (0.36) | CA2STSESR1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-21 | — | — | US | claimed |
| EP-2143432-A1 | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer | Bayer Schering Pharma AG (DE) | 2010-01-13 | — | — | EP | claimed |
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | claimed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | claimed |
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-21 | — | — | US | disclosed |
| EP-2143432-A1 | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer | Bayer Schering Pharma AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2004070009-A2 | TARGETED MULTIVALENT MACROMOLECULES | TARGESOME INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20030133972-A1 | Targeted multivalent macromolecules | TARGESOME, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | TARGESOME, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133972-A1 | Targeted multivalent macromolecules | CLTB, ILK, CD44 | CA2 4191/4885STS 4479/4885ESR1 3106/4885 |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | CA2 326/4885STS 229/4885ESR1 7/4885 |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | CD47, TSG101, ILK | CA2 3572/4885STS 3780/4885ESR1 1705/4885 |
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | ESR2, ESRRA, ESRRG | CA2 4348/4885STS 707/4885ESR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.